公开(公告)号：US20250020656A1

公开(公告)日：2025-01-16

申请号：US18784141

申请日：2024-07-25

Applicant: AJINOMOTO CO., INC.

Inventor： Naoko ARASHIDA ,  Rumi NISHIMOTO ,  Kazutaka SHIMBO ,  Hidehiro NAKAMURA ,  Natsumi NISHIKATA ,  Akira IMAIZUMI

IPC: G01N33/68 ,  G01N33/574 ,  G16H50/20

Abstract: An evaluating method includes an evaluating step of evaluating a state of lung cancer for a subject to be evaluated using a concentration value of at least one of Homoarginine, GABA, 3-Me-His, ADMA, Spermine, Spermidine, Cystathionine, Sarcosine, aAiBA, bAiBA, Putrescine, N-Acetyl-L-lys, Hypotaurine, bABA, and Ethylglycine in blood of the subject.

公开(公告)号：US20180017570A1

公开(公告)日：2018-01-18

申请号：US15715389

申请日：2017-09-26

Applicant: AJINOMOTO CO., INC.

Inventor： Naoko ARASHIDA ,  Rumi NISHIMOTO ,  Kazutaka SHIMBO ,  Hidehiro NAKAMURA ,  Natsumi NISHIKATA ,  Akira IMAIZUMI

IPC: G01N33/68 ,  G01N33/574 ,  G06F19/00

CPC classification number: G01N33/6812 ,  G01N33/57423 ,  G01N2800/56 ,  G06F19/3418 ,  G16H50/20

Abstract: An evaluating method includes an evaluating step of evaluating a state of lung cancer for a subject to be evaluated using a concentration value of at least one of Homoarginine, GABA, 3-Me-His, ADMA, Spermine, Spermidine, Cystathionine, Sarcosine, aAiBA, bAiBA, Putrescine, N-Acetyl-L-lys, Hypotaurine, bABA, and Ethylglycine in blood of the subject.

公开(公告)号：US20240277783A1

公开(公告)日：2024-08-22

申请号：US18631361

申请日：2024-04-10

Applicant: Ajinomoto Co., Inc.

Inventor： Riku USAMI ,  Miku TOYAZAKI ,  Hidehiro NAKAMURA ,  Yoshihiko MATSUDA

IPC: A61K35/744 ,  A61K35/747 ,  C07K14/50 ,  C12N15/74

CPC classification number: A61K35/744 ,  A61K35/747 ,  C07K14/503 ,  C12N15/746 ,  C07K2319/10

Abstract: Provided herein is a technology whereby a heterologous protein can be expressed in a bacterium which does not have an endogenous Tat system secretion machine. The present specification discloses a bacterium such as bifidobacteria, lactococci, and staphylococci which has been modified to express a heterologous Tat protein. The bacterium has the ability to produce and secrete a heterologous protein.

公开(公告)号：US20240091185A1

公开(公告)日：2024-03-21

申请号：US18514387

申请日：2023-11-20

Applicant: AJINOMOTO CO., INC.

Inventor： Hidehiro NAKAMURA ,  Noriko KAWASAKI ,  Yasuko KAWAMATA ,  Akihiko KITAMURA ,  Ryosei SAKAI ,  Fumika TAKEUCHI

IPC: A61K31/198 ,  A61K31/685 ,  A61P25/28

CPC classification number: A61K31/198 ,  A61K31/685 ,  A61P25/28

Abstract: Compositions, containing glycine and serine and having a content ratio of glycine to serine (glycine/serine) of not less than 0.6 in weight ratio are effective for improving cognitive function, and have an effective preventive or improving effect on a decline in cognitive function and cognitive dysfunction, are highly safe, and enable continuous ingestion or administration.

公开(公告)号：US20190228844A1

公开(公告)日：2019-07-25

申请号：US16373427

申请日：2019-04-02

Applicant: AJINOMOTO CO., INC.

Inventor： Hidehiro NAKAMURA ,  Natsumi NISHIKATA ,  Akira IMAIZUMI ,  Kazutaka SHIMBO ,  Naoko ARASHIDA ,  Rumi NISHIMOTO

IPC: G16C20/70

Abstract: An evaluating method includes an evaluating step of evaluating a state of colorectal cancer for a subject to be evaluated using (i) a concentration value of at least one metabolite of bABA, N-Me-bABA, 1-Me-His, aABA, Aminoadipic acid, bAiBA, Cadaverine, Ethylglycine, GABA, Homoarginine, Hypotaurine, Kinurenine, N6-Acetyl-L-Lys, Putrescine, Serotonin, Spermidine, Spermine, ADMA, Homocitrulline, 3-Me-His, Hydroxyproline, Phosphoethanolamine, SDMA, Acylcarnitine (13:1), and EPA in blood of the subject or (ii) a value of a formula calculated using the concentration value of the metabolite and the formula including an explanatory variable to be substituted with the concentration value of the metabolite.

公开(公告)号：US20190227071A1

公开(公告)日：2019-07-25

申请号：US16373193

申请日：2019-04-02

Applicant: AJINOMOTO CO., INC.

Inventor： Hidehiro NAKAMURA ,  Natsumi NISHIKATA ,  Akira IMAIZUMI ,  Kazutaka SHIMBO ,  Naoko ARASHIDA ,  Rumi NISHIMOTO

IPC: G01N33/574 ,  G01N33/49 ,  G01N33/487

Abstract: An evaluating method includes an evaluating step of evaluating a state of pancreatic cancer for a subject to be evaluated using (i) a concentration value of at least one metabolite of N-Me-bABA, bABA, GABA, N6-Acetyl-L-Lys, 1-Me-His, aABA, Aminoadipic acid, bAiBA, Cadaverine, Ethylglycine, Homoarginine, Hypotaurine, Kinurenine, Putrescine, Serotonin, Spermidine, Spermine, ADMA, Homocitrulline, 3-Me-His, Hydroxyproline, Phosphoethanolamine, Acylcarnitine (13:1), and EPA in blood of the subject or (ii) a value of a formula calculated using the concentration value of the metabolite and the formula including an explanatory variable to be substituted with the concentration value of the metabolite.